Abbott Laboratories (ABT) shares fell 6.51%, trading at $112.87, down $7.86, after the company reported its fourth quarter and full year 2025 results and issued its financial outlook for 2026.
The decline followed investor reaction to softer-than-expected revenue performance and a cautious interpretation of forward guidance.
Abbott said full year 2025 results reflected steady growth, but quarterly sales missed market expectations, weighing on sentiment despite earnings coming in broadly in line. The company also outlined its 2026 outlook, forecasting continued organic growth and higher adjusted earnings, though the guidance appeared insufficient to offset concerns around near-term revenue momentum across certain segments.
On the day of the announcement, ABT opened lower and traded sharply down through the session, touching an intraday low near $106 before stabilising. The stock saw an intraday high near $121, compared with a previous close around $120.7.
Trading volume was running well above the stock's average daily volume, reflecting a strong market reaction to the earnings release and outlook.
Abbott's 52-week range spans roughly the low $90 to the mid $120, highlighting recent volatility tied to earnings expectations, segment performance, and broader healthcare sector trends.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.